Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

October 4, 2016October 5, 2016

Trial Seeks Patients With Inoperable Malignant Pleural Mesothelioma

News

Boehringer Ingelheim is enrolling patients with inoperable malignant pleural mesothelioma (MPM) into a Phase 2/3 trial evaluating the effectiveness of nintedanib in combination with Alimta (pemetrexed) and Platinol (cisplatin), followed by ... Read more

September 30, 2016

Pravachol May Help Prevent Radiation-Induced Side Effects, Study Finds

News

Use of the cholesterol-lowering drug Pravachol (pravastatin) before radiation therapy markedly reduces radiation-induced toxicity, researchers observed in a mouse mesothelioma model. The study, “Pravastatin Reduces Radiation-Induced Damage to Normal Tissues,” was presented ... Read more

September 29, 2016September 29, 2016

Definitive Radiation Therapy Found to Improve Survival in People with Non-Metastatic MPM

News

Patients with non-metastatic malignant pleural mesothelioma may benefit from definitive radiation therapy, according to a large retrospective study recently presented at the American Society for Radiation 2016 Annual Meeting, held ... Read more

September 27, 2016September 27, 2016

Pleural Fluid from Mesothelioma Patients Can Induce Tumor Growth, Chemotherapy Resistance

News

Patients with malignant mesothelioma (MM) often exhibit malignant pleural effusion (MPE), a condition in which cancer causes an abnormal amount of fluid to build up in the pleural space, the ... Read more

September 26, 2016

Glucophage Doesn’t Appear to Improve Survival in Diabetics with Malignant Mesothelioma, Study Shows

News

Glucophage (metformin), an oral diabetes medicine that helps control blood sugar levels, does not improve survival among patients with type 2 diabetes and malignant pleural mesothelioma, contrary to what has ... Read more

September 23, 2016

New Bromodomain Inhibitor Shows Promise in Treating Malignant Pleural Mesothelioma

News

A new bromodomain and extraterminal (BET) inhibitor, OTX015, may be a promising approach to treat malignant pleural mesothelioma (MPM), according to a recent study published in the International Journal of ... Read more

September 20, 2016September 20, 2016

FDA Moves Galinpepimut-S, Potential Immunotherapy for Malignant Pleural Mesothelioma, to ‘Fast Track’

News

The U.S. Food and Drug Administration has granted Fast Track designation to SELLAS Life Sciences‘ WT1 cancer vaccine — galinpepimut-S — as a possible treatment of malignant pleural mesothelioma. This action ... Read more

September 19, 2016September 20, 2016

Phase 2 Study of Potential Treatment for Pleural Mesothelioma Now Recruiting Patients

News

The Baylor College of Medicine’s Mesothelioma Treatment Center at Baylor St. Luke’s Medical Center has began recruiting patients with malignant pleural mesothelioma in a clinical trial to test an investigational ... Read more

September 15, 2016

Study Identifies Signs Associated with Reoperative Surgery in Peritoneal Mesothelioma Patients

News

Abdominal pain, abdominal distention, and the presence of a tumor mass in computed tomography scans are all associated with the recurrence of malignant peritoneal mesothelioma following surgical removal of the tumor, ... Read more

September 12, 2016September 12, 2016

Exosomes Secreted by Malignant Mesothelioma Cells May Work as Diagnostic Marker

News

Malignant mesothelioma cells can secrete tiny vesicles containing a variety of proteins that educate the tumor microenvironment and lead to disease progression. In a recent study published in Scientific Reports, researchers identified the ... Read more